Current HIV Treatment Guidelines on Genvoya
Genvoya remains a recommended initial regimen for most treatment-naive adults with HIV in major U.S. guidelines, including those from the Department of Health and Human Services (DHHS). It is listed as a Preferred regimen in the Preferred and Alternative categories for certain patients, such as those without pre-treatment resistance or specific comorbidities. The fixed-dose combination—elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (EVG/c/FTC/TAF)—meets criteria for high barrier to resistance, once-daily dosing, and favorable renal/bone safety compared to older tenofovir formulations.[1]
How Genvoya Ranks Against Newer Options
Guidelines now include additional Preferred regimens like Biktarvy (bictegravir/FTC/TAF), which edges out Genvoya due to its lack of a CYP3A inhibitor (cobicistat), reducing drug interactions. Biktarvy is favored for broader use, especially in patients on interacting meds like statins or anticonvulsants. Genvoya is still Preferred for those without such issues but Alternative if interactions exist. International guidelines (e.g., EACS, BHIVA) similarly position it as effective but not first-line over INSTI-based alternatives.[1][2]
Who Still Gets Genvoya as First Choice?
It suits patients with HIV RNA <100,000 copies/mL, eGFR >50 mL/min, no HBV coinfection needing TAF adjustment, and low interaction risk. Pediatric approvals extend to ages 2+ (tablets/powder). Real-world data show 90%+ virologic suppression at 48 weeks, comparable to Biktarvy.[3]
Common Reasons It's Not Preferred Anymore
Cobicistat boosts elvitegravir but complicates dosing with many drugs, pushing guidelines toward unboosted options. Weight gain concerns with TAF-based regimens (including Genvoya) have prompted scrutiny, though less severe than EFV or DTG in some studies. Renal monitoring is still needed, but TAF improves on TDF's profile.[1][4]
Patent Status and Genvoya Availability
Gilead holds patents on Genvoya components; key U.S. patents expire 2032-2036, with no generics until then per DrugPatentWatch. Exclusivity ended in 2021, but no biosimilars or generics are approved yet. Pricing remains ~$3,500/month wholesale, though patient assistance caps copays at $0-$30.[5][6]
[1] DHHS HIV Guidelines (updated May 2024)
[2] EACS Guidelines v12.0 (2024)
[3] NEJM: GS-US-236-0112 Trial (2016, long-term data)
[4] CROI 2024: Weight Gain Meta-Analysis
[5] DrugPatentWatch: Genvoya Patents
[6] Gilead Advancing Access Program